A Phase 4 interventional study of Discontinuation of aspirin (ATC-code B01AC06 and N02BA01) in Coronary Arterial Disease (CAD), sponsored by Vestre Viken Hospital Trust. Not yet recruiting at 9 sites in Norway. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Vestre Viken Hospital Trust · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Lifelong aspirin has been a cornerstone of secondary prevention after coronary artery disease (CAD), based on trials conducted 40-50 years ago. Since then, major advances in coronary reperfusion and risk factor management have significantly improved outcomes. At the same time, aspirin is clearly associated with an increased risk of major bleeding, including intracranial haemorrhage. This raises a critical, yet unanswered question: in patients more than 2 years after a CAD event, does the benefit of continued aspirin still outweigh its bleeding risk? RELEASE-Norway is an investigator-initiated, registry-based, randomised trial with blinded endpoint assessment (PROBE design) designed to determine whether patients with chronic CAD can safely stop aspirin without losing cardiovascular protection. The trial will randomise 7,000 patients from all major hospitals in Norway. Together with a similar trial (RELEASE-Denmark, n≈7,000) planned in Denmark, the study will provide definitive evidence on the long-term net clinical benefit versus harm of aspirin in stable CAD and most likely directly inform future guidelines and clinical practice worldwide. Imaging and PROMS sub-studies will explore clinical and psychosocial mechanisms, providing insight into treatment heterogeneity and enabling future personalised antiplatelet therapy. Additionally, a health-economic analysis will assess the cost-effectiveness of discontinuing aspirin for healthcare systems.
Vestre Viken Hospital Trust is the lead sponsor of 52 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in the intervention group will be randomized to discontinuing aspirin treatment. The drug will be discontinued from their medical list. All participants will receive lifestyle advice and appropriate follow-up, as recommended.
Drug: Discontinuation of aspirin (ATC-code B01AC06 and N02BA01)
Patients will be randomized to continuation of of low-dose oral aspirin (Anatomical Therapeutic Chemical codes B01AC06 and N02BA01) at a daily dose of ≤150 mg (usual care, no intervention). All participants will receive lifestyle advice and appropriate follow-up, as recommended.
Patients will be randomized open-label 1:1 to either continuation of low-dose oral aspirin (Anatomical Therapeutic Chemical codes B01AC06 and N02BA01) at a daily dose of ≤150 mg (no intervention group) or discontinuation of aspirin therapy (intervention group). If the patient is randomized to discontinuing aspirin the treatment will be discontinued from their medical list. All participants will receive lifestyle advice and appropriate follow-up, as recommended.
Hierarchical composite endpont
The net clinical benefit of discontinuing versus continuing aspirin in patients randomized 2-8 years after an index ACS event, using a hierarchical composite endpoint with a win-ratio framework that includes: 1. Cardiovascular death, 2. Fatal bleedings, 3. Intracranial bleeding, 4. Myocardial infarctions including stent thrombosis, 5. Ischemic stroke, 6. Major bleeding (BARC 3 and 5) requiring hospitalization. The components of the endpoints will be identified in The Norwegian Patient Registry and Cause of Death Registry using procedure and diagnostic codes.
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
Risk of ischaemic disease
The cumulative risk of a composite of recurrent myocardial infarction including stent thrombosis, ischemic stroke, and cardiovascular death by randomization group. Events will be identified in the Norwegian Patient Registry and the Norwegian Cause of Death registry using procedure and diagnostic codes.
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
Risk of major bleedings
The cumulative risk of major bleedings, including intracranial and other major (BARC 3, 5) bleeding events requiring hospitalization by randomization group. Events will be identified in The Norwegian Patient Registry and the Cause of Death registry data with procedure and diagnostic codes.
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
Subgroup analyses
The net clinical benefit of discontinuing versus continuing aspirin across subgroups by age, sex, Clinical Frailty Scale score \<4 vs. ≥4 (mild frailty), single vs. multi-vessel disease, and discontinuation 2-4 years vs. 4-8 years after index event. The net clinical benefit will be analyzed the same way as for the primary endpoint: a win-ratio framework using a hierarchical composite endpoint including both ischemic events and major bleeding events.
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
Risk of individual components of the primary endpoint
The cumulative risk of the individual components of the primary endpoint by randomization group. Events will be identified in The Norwegian Patient Registry and The Norwegian Cause of Death Registry using procedure and diagnostic codes.
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
Recurrent CVD hospitalisations
The cumulative risk of recurrent hospitalization for (any) cardiovascular disease by randomization status. Hospitalizations will be identified in registry data using diagnostic and procedure codes.
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
All-cause mortality
The cumulative risk of all-cause mortality by randomization group. All-cause mortality will be obtained from the Cause of Death Registry
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
Major and minor bleedings
Cumulative risk of major or minor bleedings (BARC 2,3,5) Minor bleedings will be assessed using 10 questions based on the International Society on Thrombosis and Haemostasis (ISTH) bleeding assessment approach. Major bleedings will be identified in the Norwegian Patient registry using diagnostic and procdedure codes.
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
Gastrointestinal ulcer
The cumulative risk of gastrointestinal ulcer by randomization group. Gastroinestinal ulcer is optained from both the Norwegian Patient registry and self-reported questionnaires.
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
Malignant diseases
Cumulative risk of incident malignant diseas by randomization group. Malignant disease will be obtained from the Cancer Registry of Norway.
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
Adherence to allocated treatment
Adherence to allocated treatment evaluated by redeemed prescriptions at the pharmacy. Obtained from The Norwegian Prescription Database.
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
Health economics
Cost-utilty analysis in relation to quality of life and a healthcare utilization by randomization group. Quality of life will be obtained by the EQ-5D questionnaire and healthcare utilization will be obtained from The Norwegian Patient Registry.
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
Changes in quality of life
Changes in quality of life by randomization group measured by EQ-5D questionnaire
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
Changes in lifestyle factors
Changes in lifestyle behaviour by randomization group measured by the NORCOR Lifestyle Questionnaire. The NORCOR lifestyle questionnaire includes queestions on smoking status and quitting motiviation, alcohol consumption, physical activity and body weight and height. Smoking status: never, former, current Physical activity: Assessed by a validated questionnaire form HUNT1 which assesses frequency (never, \<once/week, once/week, two to three times/week and almost every day), intensity (light, medium and vigorous), and duration (\<15 minutes (min), 15-29 min, 30-60 min, and \>60 min) Body weight and height: Self-report body weight and height Alcohol consumption: Average number of units of alcohol consumed per week
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
Changes in angina symptoms
Changes in angina symptoms by randomization group measured by the Seattle Angina Questionnaire. The Seattle Angina Questionnaire is a validated 7-item questionnaire assessing angina frequency, symptom burden, physical limitation, and quality of life related to coronary artery disease. The summary score ranges from 0-100 and higher scores indicate better functioning, fewer physical limitations, less frequent angina, and a higher quality of life.
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
Origin of recurrent ischemic events
Risk of recurrent ischemic events by origin (previously treated PCI lesion or progression of CAD in non-target segments) and by randomization group. Information will be obtained from hospital medical records upon hospitalization for a reccurent event (a subgroup assessed by FFR/OCT) and from registry data (The Norwegian Registry of Invasive Cardiology and The Norwegian Patient Registry).
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
Patient-reported anxiety
Changes in patient-reported anxiety by randomization group using the Generalized Anxiety Disorder-2 (GAD-2) questionnaire. The total score ranges from 0-6 and a score of 3 or higher is considered a positive screen for anxiety
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
Patient reported depression
Changes in patient reported depression by randomization group measured by the Patient Health Questionnaire-2 (PHQ-2). Total score ranges from 0 to 6 and a score of 3 or higher is considered a positive screen for depression.
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
Patient-reported sleep disturbances
Changes in patient reported sleep disturbance by randomization group measured by Bergen Insomnia Scale (BIS). BIS is a validated questionnaire used to assess insomnia symptoms and sleep difficulties based on diagnostic criteria for insomnia, including sleep onset, sleep maintenance, early awakening, and daytime impairment. The Bergen Insomnia Scale (BIS) has a minimum score of 0, a maximum score of 42, and a diagnostic cutoff requiring a score of 3 or higher on at least one of the first four items (nighttime symptoms) combined with 3 or higher on at least one of the last two items (daytime consequences/dissatisfaction).
Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up
Plan to share: No — Individual participant-level data cannot be made publicly available due to data protection regulations and applicable Norwegian legislation.
No publications or documents are linked to this record.
Start is estimated for Feb 2027; primary completion for Dec 2030, 46 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vestre Viken Hospital Trust